The efficacy results of several trials have been uneven in the metastatic scenario, despite the FDA’s approval of the CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib for the treatment of patients with metastatic HR-positive/HER2-negative breast cancer. The gene discussed is ERBB2; the disease is breast cancer.